MedPacto, Inc. (KOSDAQ:235980)
3,655.00
-100.00 (-2.66%)
Nov 20, 2026, 3:30 PM KST
MedPacto Revenue
MedPacto had revenue of 1.00B KRW in the quarter ending September 30, 2026, a decrease of -16.31%. This brings the company's total for the last twelve months to 4.80B, up 94.37% year-over-year. In the year 2025, MedPacto had annual revenue of 3.90B. That makes MedPacto the 41,044th largest company in the world by revenue and 2,527th in South Korea.
Revenue (ttm)
4.80B
Revenue Growth
+94.37%
P/S Ratio
26.10
Revenue / Employee
85.70M
Employees
56
Market Cap
125.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.90B | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bioneer | 345.88B |
| GC Cell | 162.00B |
| HLB Therapeutics | 64.45B |
| GC Genome | 32.64B |
| Anterogen.Co.,Ltd. | 9.29B |
| NeoImmuneTech | 6.60B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |